Efficacy of MK615 for the treatment of patients with liver disorders

doi:10.3748/wjg.v18.i31.4118

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 31

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5204)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-4) series, Tables (1-3) series.

Item

Count

PDF

508

HTML

4279

Figures (1-4)

223

Tables (1-3)

194

Sum=5204

Aug 21, 2012 (publication date) through Dec 20, 2024

Times Cited of This Article

Times Cited (13)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Original Article

World J Gastroenterol. Aug 21, 2012; 18(31): 4118-4126
Published online Aug 21, 2012. doi: 10.3748/wjg.v18.i31.4118

Full Size Figure Download Figure

Figure 2 Effect of MK615 in D-galactosamine hydrochloride-induced acute hepatic injury in rats. A: AST plasma levels; B: ALT plasma levels; C: Control group (liver); D: MK615 group (liver). AST:Aspartate aminotransferase; ALT: Alanine aminotransferase.

Citation: Hokari A, Ishikawa T, Tajiri H, Matsuda T, Ishii O, Matsumoto N, Okuse C, Takahashi H, Kurihara T, Kawahara KI, Maruyama I, Zeniya M. Efficacy of MK615 for the treatment of patients with liver disorders. World J Gastroenterol 2012; 18(31): 4118-4126
URL: https://www.wjgnet.com/1007-9327/full/v18/i31/4118.htm
DOI: https://dx.doi.org/10.3748/wjg.v18.i31.4118